Dear Potential Investor,

I’m an engineer, physician, and allergist. My chemistry partner, Prof. Catherine Yang, and I discovered and patented the world’s first and only safe and effective allergy treatment for poison ivy (PI) and oak (PO).
We are now seeking investors to help us bring this product to market.

Nomenclature

In normal times our product would be an allergy vaccine, but the term “vaccine” has become divisive. We don’t want to alienate potential users who won’t take anything called a vaccine so we’re calling it what a vaccine is, an antigen used for immunotherapy.

Revolutionary Allergy Treatment for PI and PO

We’re proud to have developed and patented the first safe and effective immunotherapy antigen for PI and PO. Our treatment, to be a five-to-seven shot initial series with annual boosters, delivered 90-100% efficacy with no significant adverse reactions in our peer-reviewed human proof-of-concept series.

Why This Matters

Approximately 175 million Americans will seek medical care one or more times for allergic reactions to PI and PO. For 11 to 18 million of these, avoidance is either not possible or not practical, leaving them wanting a treatment that’s safe, effective, convenient, and affordable. For over a century, scientists have attempted to solve this problem, without success – until now.

Prof. Yang and I discovered and patented a new and potent way to feed antigens to the immune system. This gave us the first successful induction of true immunological tolerance in a patient previously sensitized to PI or PO in the more than 100 years that scientists have been trying to achieve this goal.

An allergist can lawfully make and modify allergenic products for his own patients. This let us adjust our dose and formulation until we achieved a 90% response to initial treatment with a 100% response of initial non-responders to a single booster dose. We had no significant adverse effects. This work will let us bring our antigen to market for about 10% of what it would otherwise cost to develop a new immunotherapy antigen.

The FDA acknowledged our human proof-of-concept work with a low cost, fast-track pathway to approval with no scientific or technical obstacles. We designed a simple, cost-effective series of cultivation and manufacturing steps with which we expect to bring our product to market within three to four years from receipt of Round 1 funding.

The work we were able to do in my practice reduces our cost to market from a typical ~$200M to only $21M. Our having a formulation that already satisfied the FDA’s clinical trial requirements removes a similar 90+% of the typical new drug risk of failure. With a market of 11 to 18 million Americans and no effective competition, we see an uncommonly favorable reward to risk ratio for a biotechnology start-up company.